A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes

A Phase 4 Study to Evaluate Glucodynamic Effects of Dulaglutide in Japanese Patients With Type 2 Diabetes Mellitus

The purpose of this study is to evaluate the glucodynamic effects of dulaglutide in Japanese participants with type 2 diabetes mellitus.

Inclusion Criteria:

• Have type 2 diabetes (based on the World Health Organization [WHO] diagnostic criteria) for at least 1 year.
• Have diet and exercise therapy only (no oral antihyperglycemic medication for at least 3 months prior to screening).
• Have a fasting blood glucose value of ≥120 and ≤200 milligrams per deciliter (mg/dL) at screening.
• Have a screening body weight of ≥50 and ≤80 kilograms.

Exclusion Criteria:

• Have known allergies to dulaglutide, or other glucagon-like peptide-1 (GLP-1) receptor agonists.
• Have had a clinically significant cardiovascular disease.
• Have a known clinically significant gastric emptying abnormality or have undergone gastric bypass surgery or restrictive bariatric surgery.
• Have acute or chronic hepatitis, signs and symptoms of any other liver disease.
• Have a history of chronic pancreatitis or acute idiopathic pancreatitis, or were diagnosed with any type of acute pancreatitis.
• Have an estimated glomerular filtration rate (eGFR) <30 milliliters/minute/1.73 meter squared.
• In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study.